Dollar Tree vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Chesapeake VA value retail (NASDAQ: DLTR) at $17.6B FY2024 revenue; Family Dollar sold for $1B (2025, vs. $9.5B acquired 2015), multi-price 3.0 format ($1.25-$7) in 2,900 stores competing with Dollar General for value shoppers.
About
Dollar Tree, Inc. is a Chesapeake, Virginia-based discount variety retailer — publicly traded on NASDAQ (NASDAQ: DLTR) as an S&P 500 Consumer Staples component — operating as a Fortune 200 company with approximately 16,000 stores across 48 states and five Canadian provinces through over 214,000 employees, with fiscal year 2024 revenue of $17.6 billion. The company's defining strategic development of 2025 was the completion of the sale of its Family Dollar business to Brigade Capital Management and Macellum Capital Management for just over $1 billion — a $8.5 billion write-down from the original $9.5 billion Family Dollar acquisition price in 2015, marking one of the largest retail acquisition failures in recent history. The divestiture concentrates Dollar Tree on its core namesake banner, which has undergone its own transformation: the company raised prices from $1.00 to $1.25 in 2022 (the first price increase in 36 years of the $1 fixed-price promise) and has expanded approximately 2,900 stores to the multi-price "3.0" format offering products up to $7. Founded in 1986 by Macon Brock and Doug Perry in Norfolk, Virginia as a single-price point variety store, Dollar Tree grew to become the dominant US single-price-point retailer before the ill-fated Family Dollar acquisition transformed it into a dual-banner company trying to serve both the $1-focused impulse buyer and the neighborhood dollar store shopper.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.